Omicia, Inc., an Oakland, CA-based provider of clinical genome interpretation and reporting software, completed a $23m Series B financing round.
Backers included new investors UPMC Enterprises, Roche Venture Fund, LDV Partners, Ping An Ventures, and a large genomics investor, as well as existing investors ARTIS Ventures, Acadia Woods Partners and Buchanan Investments.
The company intends to use the funds to accelerate product development, expansion in sales, sales support, marketing and operations, and extend variations of its flagship OpalTM Clinical platform for use in new geographies and new verticals including life science research, clinical trial support, population health management and consumer applications.
Led by Matt Tindall, CEO, Omicia provides a software platform for healthcare system stakeholders with next generation sequence (NGS) interpretation and reporting capabilities to drive improved clinical outcomes, as well as an option to scale production in a HIPAA-compliant, cloud-enabled environment.
In addition, the company’s OpalTM Clinical platform leverages a deep variant data warehouse to deliver high-throughput results to assist lab partners with automated diagnostic reporting.